JP2021506953A - 化膿性汗腺炎の治療に使用するための抗ｃｄ４０抗体 - Google Patents

化膿性汗腺炎の治療に使用するための抗ｃｄ４０抗体 Download PDF

Info

Publication number
JP2021506953A
JP2021506953A JP2020539848A JP2020539848A JP2021506953A JP 2021506953 A JP2021506953 A JP 2021506953A JP 2020539848 A JP2020539848 A JP 2020539848A JP 2020539848 A JP2020539848 A JP 2020539848A JP 2021506953 A JP2021506953 A JP 2021506953A
Authority
JP
Japan
Prior art keywords
antibody
seq
dose
treatment
cfz533
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020539848A
Other languages
English (en)
Japanese (ja)
Inventor
エスピー，パスカル
レッシェ，クリスチャン
ロス，ルーカス
ラッシュ，ジェームス
ヴィツォレク，グラジナ
Original Assignee
ノバルティス アーゲー
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー, ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2021506953A publication Critical patent/JP2021506953A/ja
Priority to JP2021109796A priority Critical patent/JP7558900B2/ja
Priority to JP2024161056A priority patent/JP2024178278A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2020539848A 2019-01-11 2020-01-09 化膿性汗腺炎の治療に使用するための抗ｃｄ４０抗体 Pending JP2021506953A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021109796A JP7558900B2 (ja) 2019-01-11 2021-07-01 化膿性汗腺炎の治療に使用するための抗ｃｄ４０抗体
JP2024161056A JP2024178278A (ja) 2019-01-11 2024-09-18 化膿性汗腺炎の治療に使用するための抗ｃｄ４０抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19151461.1 2019-01-11
EP19151461 2019-01-11
PCT/IB2020/050132 WO2020144605A1 (en) 2019-01-11 2020-01-09 Anti-cd40 antibodies for use in treatment of hidradenitis suppurativa

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021109796A Division JP7558900B2 (ja) 2019-01-11 2021-07-01 化膿性汗腺炎の治療に使用するための抗ｃｄ４０抗体

Publications (1)

Publication Number Publication Date
JP2021506953A true JP2021506953A (ja) 2021-02-22

Family

ID=65019425

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020539848A Pending JP2021506953A (ja) 2019-01-11 2020-01-09 化膿性汗腺炎の治療に使用するための抗ｃｄ４０抗体
JP2021109796A Active JP7558900B2 (ja) 2019-01-11 2021-07-01 化膿性汗腺炎の治療に使用するための抗ｃｄ４０抗体
JP2024161056A Withdrawn JP2024178278A (ja) 2019-01-11 2024-09-18 化膿性汗腺炎の治療に使用するための抗ｃｄ４０抗体

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021109796A Active JP7558900B2 (ja) 2019-01-11 2021-07-01 化膿性汗腺炎の治療に使用するための抗ｃｄ４０抗体
JP2024161056A Withdrawn JP2024178278A (ja) 2019-01-11 2024-09-18 化膿性汗腺炎の治療に使用するための抗ｃｄ４０抗体

Country Status (13)

Country Link
US (1) US12435150B2 (enExample)
EP (1) EP3908310A1 (enExample)
JP (3) JP2021506953A (enExample)
KR (1) KR20210114964A (enExample)
CN (1) CN113271964A (enExample)
AU (1) AU2020205839A1 (enExample)
BR (1) BR112021013174A2 (enExample)
CA (1) CA3125886A1 (enExample)
CL (1) CL2021001829A1 (enExample)
IL (1) IL284338A (enExample)
MX (1) MX2021008305A (enExample)
TW (1) TW202033558A (enExample)
WO (1) WO2020144605A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022061061A1 (en) * 2020-09-21 2022-03-24 Boehringer Ingelheim International Gmbh Use of anti-cd40 antibodies for treatment of inflammatory conditions
CA3202891A1 (en) 2021-01-28 2022-08-04 Kara Olson Compositions and methods for treating cytokine release syndrome
MX2024001877A (es) 2021-08-10 2024-02-28 Kymab Ltd Tratamiento de dermatitis atopica.
US20250304680A1 (en) * 2022-05-17 2025-10-02 The Uab Research Foundation Methods and compositions for treating or preventing inflammatory skin disorders
TW202515607A (zh) * 2023-06-20 2025-04-16 英商凱麥博有限公司 Ox40及ox40l調節劑治療化膿性汗腺炎之用途
IL328258A (en) * 2024-01-03 2026-07-01 Abbvie Inc Luticizumab for use in the treatment of hidradenitis suppurativa
US20250277048A1 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. The use of cd40 inhibitors for inhibiting an immune response and enabling immunogen administration and re-administration
WO2025184567A1 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response
WO2025235670A1 (en) 2024-05-07 2025-11-13 Eledon Pharmaceuticals, Inc. Use of anti-cd40 ligand antibodies for immunosuppression in islet cell transplantation
WO2025235683A1 (en) 2024-05-07 2025-11-13 Eledon Pharmaceuticals, Inc. Methods and compositions for prevention of transplant rejection

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014500720A (ja) * 2010-11-15 2014-01-16 ノバルティス アーゲー 抗ＣＤ４０抗体のサイレントＦｃ変異体
JP2018520654A (ja) * 2015-05-29 2018-08-02 アッヴィ・インコーポレイテッド 抗ｃｄ４０抗体およびその使用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US20050136055A1 (en) 2003-12-22 2005-06-23 Pfizer Inc CD40 antibody formulation and methods
EP1707627B1 (en) 2003-12-25 2012-11-14 Kyowa Hakko Kirin Co., Ltd. Antagonistic anti-CD40 antibody mutant
EP1854810A1 (en) 2006-05-09 2007-11-14 PanGenetics B.V. Deimmunized antagonistic anti-human CD40 monoclonal antibody from the ch5D12 antibody
EP2796467B1 (en) 2010-03-31 2018-03-28 Boehringer Ingelheim International GmbH Anti-CD40 antibodies
ES2711100T3 (es) * 2011-03-07 2019-04-30 Celgene Corp Métodos para tratar enfermedades usando compuestos isoindolina
JO3425B1 (ar) 2013-07-15 2019-10-20 Novartis Ag مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b
RU2020117156A (ru) * 2017-12-01 2022-01-04 Эббви Инк. Конъюгаты анти-cd40 антитела и лекарственного средства

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014500720A (ja) * 2010-11-15 2014-01-16 ノバルティス アーゲー 抗ＣＤ４０抗体のサイレントＦｃ変異体
JP2018520654A (ja) * 2015-05-29 2018-08-02 アッヴィ・インコーポレイテッド 抗ｃｄ４０抗体およびその使用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MEDICINE, 2014, VOL.93, NO. 27, PP.1-11, JPN6020050588, ISSN: 0004416937 *

Also Published As

Publication number Publication date
WO2020144605A1 (en) 2020-07-16
TW202033558A (zh) 2020-09-16
US20220098315A1 (en) 2022-03-31
EP3908310A1 (en) 2021-11-17
JP2021181439A (ja) 2021-11-25
BR112021013174A2 (pt) 2021-11-03
US12435150B2 (en) 2025-10-07
CA3125886A1 (en) 2020-07-16
AU2020205839A1 (en) 2021-06-03
CN113271964A (zh) 2021-08-17
MX2021008305A (es) 2021-08-24
KR20210114964A (ko) 2021-09-24
JP2024178278A (ja) 2024-12-24
JP7558900B2 (ja) 2024-10-01
IL284338A (en) 2021-08-31
CL2021001829A1 (es) 2022-04-22

Similar Documents

Publication Publication Date Title
JP7558900B2 (ja) 化膿性汗腺炎の治療に使用するための抗ｃｄ４０抗体
JP6861301B2 (ja) 移植片拒絶の予防に使用するための抗ｃｄ４０抗体
US20250206833A1 (en) Anti-CD40 Antibodies for Use in Treatment of Sjogren's Syndrome
TWI875757B (zh) T1dm和胰島炎治療中使用之抗cd40抗體
TW202302640A (zh) 抗tl1a抗體組合物及肺中之治療方法
WO2012059598A2 (en) Methods of treating rheumatoid arthritis using il-17 antagonists
RU2790558C2 (ru) Антитела к cd40 для применения в лечении синдрома шегрена
WO2025083621A1 (en) Treatment of hidradenitis suppurativa using anti-baff-r antibodies

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200729

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20200729

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20201211

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210105

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210301

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210914